Glyceryl Ascorbic Acid Derivative for Atopic Dermatitis Cytokine Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing atopic dermatitis improving agents do not sufficiently address the production and expression of interleukin-33 and interleukin-1, which are key cytokines exacerbating atopic dermatitis.
Innovation Solution
A glyceryl ascorbic acid acylated derivative, represented by formula (I), is used to inhibit the production and expression of interleukin-33 and interleukin-1, thereby improving atopic dermatitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional atopic dermatitis improving agents (DHA/EPA ointment or tacrolimus ointment) are used, then lipid mediator production is inhibited, but interleukin-33 and interleukin-1 production and expression are not sufficiently suppressed
Solution Approach 1:
The patent employs parameter changes by utilizing a specific derivative of glyceryl ascorbic acid with particular chemical structure parameters (formula (I)) that exhibits enhanced biological activity. This derivative demonstrates superior ability to suppress interleukin-33 and interleukin-1 production and expression compared to conventional agents, thereby resolving the contradiction between reliable cytokine inhibition and therapeutic efficacy
Solution Approach 2:
The invention uses a composite approach by combining the glyceryl ascorbic acid derivative with specific fatty acid chains (represented by formula (I) where R1-R6 are specific combinations of hydrogen, methyl, and other groups). This composite molecular structure achieves both reliable interleukin suppression and improved atopic dermatitis treatment outcomes
Data Source
AI summary
Provided are an atopic dermatitis improving agent and the like including a glyceryl ascorbic acid acylated derivative having a specific molecular structure.